论文部分内容阅读
目的:分析孟鲁司特与沙美特罗替卡松粉吸入剂对支气管哮喘患儿的临床疗效及对血清炎性因子的影响。方法:选取2014年6月—2016年5月间儿科收治的支气管哮喘患儿80例为研究对象,按照完全随机对照原则将其分为对照组和观察组,每组40例;对照组患儿给予沙美特罗替卡松粉吸入剂治疗,观察组患儿在对照组治疗基础上,加用孟鲁司特治疗,同时治疗3疗程(12周),比较两组患儿的临床疗效、治疗前后炎症因子水平。结果:经治疗后,观察组患者的总有效率为95.00%高于对照组为60.00%(P<0.05),血清炎性因子IL-6和TNF-α水平低于对照组(P<0.05)。结论:孟鲁司特与沙美特罗替卡松用于治疗儿童支气管哮喘的疗效较为确切,能够有效降低血清炎性因子水平,且安全性较高。
Objective: To analyze the clinical efficacy of montelukast and salmeterol and fluticasone in inhalation on bronchial asthma in children and its effect on serum inflammatory factors. Methods: Eighty children with bronchial asthma admitted to our department from June 2014 to May 2016 were selected as the research objects. According to the principle of complete randomization, they were divided into control group and observation group, 40 cases in each group. The control group The patients in the observation group were treated with montelukast plus 3 courses of treatment (12 weeks) at the same time. The clinical curative effect and treatment of the two groups were compared Before and after the level of inflammatory cytokines. Results: After treatment, the total effective rate in the observation group was 95.00%, which was significantly higher than that in the control group (60.00%, P <0.05). Serum inflammatory cytokines IL-6 and TNF-α were lower than those in the control group . Conclusion: Montelukast and salmeterol / fluticasone are more effective in the treatment of children with bronchial asthma, which can effectively reduce serum levels of inflammatory cytokines and have higher safety.